Putative role of the mTOR/4E-BP1 signaling pathway in the carcinogenesis and progression of gastric cardiac adenocarcinoma
Open Access
- 28 November 2012
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 7 (2) , 537-542
Abstract
The mammalian target of rapamycin/eukaryotic translation inititiation factor 4E binding protein 1 (mTOR/4E-BP1) transduction pathway is activated in a range of malignant cancers, but its role in human gastric cardiac adenocarcinoma (GCA) has not been well defined. The present study used western blotting and reverse transcription polymerase chain reaction (RT-PCR) to assess the expression of mTOR, 4E-BP1 and eukaryotic translation initiation factor 4E (eIF4E) at the protein and mRNA levels in 33 cases of GCA and paired adjacent normal gastric mucosal tissues. The expression of mTOR at the protein level in GCA was significantly lower than that in the corresponding normal gastric mucosa (0.296 ± 0.27 vs. 1.348 ± 0.80, P<0.05), but the ratio of p-mTOR to mTOR was significantly increased in tumor tissues (1.425 ± 1.07 vs. 0.450 ± 0.24, P<0.05). The expression of 4E-BP1 was significantly decreased in GCA compared with normal tissues (p<0.05), while the levels of phosphorylated 4E-BP1 (p-4E-BP1) were markedly increased in tumor tissues (p<0.05). The levels of phosphorylated eIF4E (p‑eIF4E) were significantly higher in the tumors in comparison to the corresponding normal tissues (1.822 ± 0.63 vs. 0.997 ± 0.38, P<0.05), and the levels of p-eIF4E were closely correlated with lymph node metastasis (p<0.05). The mTOR/4E-BP1 signaling pathway is activated in GCA, with mTOR activated mainly through increased mTOR phosphorylation rather than protein overexpression.Keywords
This publication has 37 references indexed in Scilit:
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumBritish Journal of Cancer, 2012
- Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal CancerJournal of the American College of Surgeons, 2010
- Overexpression of Phosphorylated 4E-BP1 Predicts for Tumor Recurrence and Reduced Survival in Cervical Carcinoma Treated With Postoperative RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- 4E‐BP1 is a target of Smad4 essential for TGFβ‐mediated inhibition of cell proliferationThe EMBO Journal, 2009
- The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potentialBiochemical and Biophysical Research Communications, 2009
- Relation between outcomes and localisation of p-mTOR expression in gastric cancerBritish Journal of Cancer, 2009
- Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomachBritish Journal of Cancer, 2007
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45Journal of Cancer Research and Clinical Oncology, 2004